Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

Simon Fraser University

$35,000.00

Structures and Mechanisms of Reactive Metal Centres: Metal-based Drugs and Bioinorganic Catalysts

EF 2014-15

Résumé
Our research is developing metal-based anticancer compounds and novel bioinorganic catalysts. To probe structure-activity relationships in these systems, we use a combination of spectroscopic methods to characterize paramagnetic metal centres, intermediates, and radical species. These mechanistic studies are leading our design and synthesis of reactive metal complexes and new reaction systems. (i) Ruthenium-based chemotherapeutics have shown great promise in clinical studies. We are developing new Ru(III) anticancer compounds that target interactions with albumin for selective delivery to cancer cells. Using magnetic resonance spectroscopic methods, we are studying protein mediated intercellular transport and the fate of these compounds in cellular environments.(ii) Reduction of Ru(III) complexes in vivo can activate them towards ligand exchange with biomolecules. We are preparing complexes with redox-active ligands, whose reduction potentials can be tuned by aqueous and biomolecule ligand exchange in vivo. These compounds target the hypoxic, reducing environment of tumours for selective activation, both by production of activated Ru(II) species and reactive oxygen species.(iii) Solvent systems that are comprised only of cations and anions provide unique environments for biocatalysis. We are using biocompatible ""ionic liquids"" with heme proteins such as cytochrome c to develop new systems for selective oxidations and hydroxylations. Mechanistic studies guide our design of new catalysts and provide insight into the influence of solvent effects on the chemistry of metalloproteins.(iv) We are developing biomimetic porphyrin and non-heme iron catalysts, using ionic liquids to act as non-biological substitutes for the protein environment at the active sites of metalloenzymes. Studies of reactivity and reaction intermediates allow us to determine how the ionic liquids influence catalytic mechanisms. This work seeks to develop new catalytic systems whose utility is tailored by the tunable solvent environment of ionic liquids.
Programme
Discovery Grants Program - Individual
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
312575-2012
Name nom
Walsby, Charles
Department département
Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2012
Award amount
35000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1202
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Physical sciences
Area of application fr
Sciences physiques
Research subject code
3603
Research subject group en
Inorganic chemistry
Research subject group fr
Chimie inorganique
Research subject en
Bio-inorganic chemistry
Research subject fr
Chimie bio-inorganique
Partie
3
Nb partie
5
Application title
Structures and Mechanisms of Reactive Metal Centres: Metal-based Drugs and Bioinorganic Catalysts
Keyword
NSERC
Application summary
Our research is developing metal-based anticancer compounds and novel bioinorganic catalysts. To probe structure-activity relationships in these systems, we use a combination of spectroscopic methods to characterize paramagnetic metal centres, intermediates, and radical species. These mechanistic studies are leading our design and synthesis of reactive metal complexes and new reaction systems. (i) Ruthenium-based chemotherapeutics have shown great promise in clinical studies. We are developing new Ru(III) anticancer compounds that target interactions with albumin for selective delivery to cancer cells. Using magnetic resonance spectroscopic methods, we are studying protein mediated intercellular transport and the fate of these compounds in cellular environments.(ii) Reduction of Ru(III) complexes in vivo can activate them towards ligand exchange with biomolecules. We are preparing complexes with redox-active ligands, whose reduction potentials can be tuned by aqueous and biomolecule ligand exchange in vivo. These compounds target the hypoxic, reducing environment of tumours for selective activation, both by production of activated Ru(II) species and reactive oxygen species.(iii) Solvent systems that are comprised only of cations and anions provide unique environments for biocatalysis. We are using biocompatible ""ionic liquids"" with heme proteins such as cytochrome c to develop new systems for selective oxidations and hydroxylations. Mechanistic studies guide our design of new catalysts and provide insight into the influence of solvent effects on the chemistry of metalloproteins.(iv) We are developing biomimetic porphyrin and non-heme iron catalysts, using ionic liquids to act as non-biological substitutes for the protein environment at the active sites of metalloenzymes. Studies of reactivity and reaction intermediates allow us to determine how the ionic liquids influence catalytic mechanisms. This work seeks to develop new catalytic systems whose utility is tailored by the tunable solvent environment of ionic liquids.